<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "http://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2" xml:lang="en">
    <front>
        <journal-meta>
            <journal-id journal-id-type="pmc">F1000Research</journal-id>
            <journal-title-group>
                <journal-title>F1000Research</journal-title>
            </journal-title-group>
            <issn pub-type="epub">2046-1402</issn>
            <publisher>
                <publisher-name>F1000 Research Limited</publisher-name>
                <publisher-loc>London, UK</publisher-loc>
            </publisher>
        </journal-meta>
        <article-meta>
            <article-id pub-id-type="doi">10.12688/f1000research.26731.1</article-id>
            <article-categories>
                <subj-group subj-group-type="heading">
                    <subject>Research Article</subject>
                </subj-group>
                <subj-group>
                    <subject>Articles</subject>
                </subj-group>
            </article-categories>
            <title-group>
                <article-title>Bioinformatic study to discover natural molecules with activity against COVID-19</article-title>
                <fn-group content-type="pub-status">
                    <fn>
                        <p>[version 1; peer review: 2 approved]</p>
                    </fn>
                </fn-group>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author" corresp="no">
                    <name>
                        <surname>Singh</surname>
                        <given-names>Sweta</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Formal Analysis</role>
                    <role content-type="http://credit.niso.org/">Investigation</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Original Draft Preparation</role>
                    <uri content-type="orcid">https://orcid.org/0000-0001-9296-5149</uri>
                    <xref ref-type="aff" rid="a1">1</xref>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                    <name>
                        <surname>Florez</surname>
                        <given-names>Hector</given-names>
                    </name>
                    <role content-type="http://credit.niso.org/">Funding Acquisition</role>
                    <role content-type="http://credit.niso.org/">Methodology</role>
                    <role content-type="http://credit.niso.org/">Supervision</role>
                    <role content-type="http://credit.niso.org/">Writing &#x2013; Review &amp; Editing</role>
                    <uri content-type="orcid">https://orcid.org/0000-0002-5339-4459</uri>
                    <xref ref-type="corresp" rid="c1">a</xref>
                    <xref ref-type="aff" rid="a2">2</xref>
                </contrib>
                <aff id="a1">
                    <label>1</label>Savitribai Phule Pune University, Pune, India</aff>
                <aff id="a2">
                    <label>2</label>Universidad Distrital Francisco Jose de Caldas, Bogota, Colombia</aff>
            </contrib-group>
            <author-notes>
                <corresp id="c1">
                    <label>a</label>
                    <email xlink:href="mailto:haflorezf@udistrital.edu.co">haflorezf@udistrital.edu.co</email>
                </corresp>
                <fn fn-type="conflict">
                    <p>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>6</day>
                <month>10</month>
                <year>2020</year>
            </pub-date>
            <pub-date pub-type="collection">
                <year>2020</year>
            </pub-date>
            <volume>9</volume>
            <elocation-id>1203</elocation-id>
            <history>
                <date date-type="accepted">
                    <day>30</day>
                    <month>9</month>
                    <year>2020</year>
                </date>
            </history>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2020 Singh S and Florez H</copyright-statement>
                <copyright-year>2020</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <self-uri content-type="pdf" xlink:href="https://f1000research.com/articles/9-1203/pdf"/>
            <abstract>
                <p>
                    <bold>Background:</bold> In 2020, the world has struggled to deal with coronavirus disease 2019 (COVID-19), which started in 2019 in China and has spread throughout the globe, affecting at least 31,175,835 humans globally and claiming 962,634 lives reported till 22
                    <sup>nd </sup>September, 2020 by the World Health Organization. The main causative agent for this disease is known as severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). So far, there is no cure or proven therapeutics available till date. Therefore, we undertook this study to find the most probable drug candidate through a bioinformatics study.</p>
                <p>
                    <bold>Methods:</bold> Thus, we virtually screened the Zinc natural database using HTVS tool through molecular docking studies to analyze molecules recommended for the treatment of COVID-19.</p>
                <p>
                    <bold>Results:</bold>Ramipril benzyl ester, propafenone dimer and Lariciresinol are three important drugs found from the present study due to their medicinal application which could be helpful in treating the disease. Stylopine, quillaic acid, cinobufagin, vitisinol C, segetalin A, scopolamine, 3-oxo glycyrrhetinic acid, conchinone B, lactimidomycin and cardinalins 4 are the other lead molecules that could be used as therapeutics against COVID-19 disease.</p>
                <p>
                    <bold>Conclusions:</bold> The studied molecules could act as an effective inhibitory drug against COVID-19.</p>
            </abstract>
            <kwd-group kwd-group-type="author">
                <kwd>COVID-19</kwd>
                <kwd>SARS-CoV-2</kwd>
                <kwd>Molecular Docking</kwd>
                <kwd>High throughput virtual screening</kwd>
            </kwd-group>
            <funding-group>
                <award-group id="fund-1">
                    <funding-source>Universidad Distrital Francisco Jose de Caldas</funding-source>
                </award-group>
                <funding-statement>This work was supported by the research group Information Technologies Innovation (ITI) (https://www.itiud.org/), which belongs to the Universidad Distrital Francisco Jose de Caldas located in Bogot&#x00e1; Colombia. </funding-statement>
                <funding-statement>
                    <italic>The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</italic>
                </funding-statement>
            </funding-group>
        </article-meta>
    </front>
    <body>
        <sec sec-type="intro">
            <title>Introduction</title>
            <p>A novel virus was first found infecting human in China on 30
                <sup>th </sup>December, 2019. The causative agent for this disease was found to be severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Coronavirus disease 2019 (COVID-19) was declared as a pandemic by the World Health Organization on 11
                <sup>th </sup>March, 2020. The virus has been responsible for &#x2019;locking down&#x2019; much of the human race in most countries of the world for several months. The infectivity of this virus is extremely high and the mortality of this disease is around 5&#x2013;7 percentage of the total infected cases
                <sup>
                    <xref ref-type="bibr" rid="ref-1">1</xref>
                </sup>. However, the infection fatality rate was reported to be 0.5&#x2013;3.6% and the case fatality rate 2.3&#x2013;7.2%, as per other reports since it differs from region to region over time
                <sup>
                    <xref ref-type="bibr" rid="ref-2">2</xref>
                </sup>
            </p>
            <p>Coronaviruses consist of an enveloped RNA genome, and these viruses are zoonotic in nature. They cause respiratory, hepatic neurological, and enteric diseases in birds and mammals. As per the recent reports, this disease has claimed 962,634 lives worldwide, infecting 31,175,835 people globally till 22
                <sup>nd </sup>September, 2020
                <sup>
                    <xref ref-type="bibr" rid="ref-3">3</xref>
                </sup>. SARS-CoV-2 consists of 30 kb nucleotides as its genome
                <sup>
                    <xref ref-type="bibr" rid="ref-4">4</xref>
                </sup>. Two polyproteins essential for replication and transcription, pp1a and pp1ab, are encoded by the SARS CoV-2 replicase gene. The main protease (3C-like protease) or Mpro (a 33.8 kDa protein) is responsible for releasing the functional viral polypeptides from polyproteins after cleaving pp1a and pp1ab
                <sup>
                    <xref ref-type="bibr" rid="ref-4">4</xref>
                </sup>. Therefore, Mpro is identified as an important drug target owing to its functional significance in the life cycle of the virus and also due to the absence of its homologues in the human race
                <sup>
                    <xref ref-type="bibr" rid="ref-4">4</xref>
                </sup>.</p>
            <p>A few drugs such as hydroxychloroquine and remdesivir that were found via bioinformatics approach have been reported. Hydroxychloroquine is a drug that is presently used against malaria. But when it was tested on SARS-CoV-2 virus, it showed activity against the virus in vitro. However, it was not found to be effective against the virus in COVID 19 patients during clinical trials
                <sup>
                    <xref ref-type="bibr" rid="ref-5">5</xref>,
                    <xref ref-type="bibr" rid="ref-6">6</xref>
                </sup>. Later, this drug was prohibited from use in certain countries due to it side effects. Remdesivir is an antiviral drug that was found to show activity against the virus and it did inhibit the SARS-CoV-2 virus to certain extent. Remdesivir is presently used against COVID-19 in certain countries
                <sup>
                    <xref ref-type="bibr" rid="ref-7">7</xref>
                </sup>.</p>
            <p>In the present work, we carried out high throughput virtual screening (HTVS). It is a rapid way to search for the potential drug against the target. HTVS of Zinc natural database was performed through Python prescription software known as PyRx. This software has in built dock, Vina and Autodock tools along with openbabel. Autodock software utilizes MGLTools that has computer aided drug discovery pipeline. CADD is required for virtual high throughput screening of large databases for probable hits as therapeutic agents. This type of virtual screening helps to dock several ligands on one protein. PyRx is publicly obtainable HTVS software. Analysis and identification of distinct poses visibly and using a scoring algorithm quantitatively forms two basis of docking technique
                <sup>
                    <xref ref-type="bibr" rid="ref-8">8</xref>
                </sup>.</p>
            <p>The free binding energy (&#x0394;G) between the protein and the ligands is calculated in docking. The free binding energy, thus calculated, forms the foundations of complex systems of subjects such as molecular biology and biochemistry
                <sup>
                    <xref ref-type="bibr" rid="ref-8">8</xref>
                </sup>.</p>
        </sec>
        <sec sec-type="methods">
            <title>Methods</title>
            <sec>
                <title>Molecule selection</title>
                <p>As per our earlier published article
                    <sup>
                        <xref ref-type="bibr" rid="ref-8">8</xref>
                    </sup>, we found that fexofenadine acetate (Allegra), atovaquone, ethamidindole, baicalin,justicidin D, euphol,curine and glycyrrhetic acid could be used as COVID-19 inhibitory drugs
                    <sup>
                        <xref ref-type="bibr" rid="ref-8">8</xref>
                    </sup>. In that article, we selected 129 known drugs for drug repurposing, from which we found atovaquone, presently in use for treating malaria and 
                    <italic toggle="yes">Pneumocystis carinii</italic> pneumonia. We had considered another aspect in which we had taken 992 small molecules from Zinc natural database from which fexofenadine acetate (Allegra), an already in use drug for anti-allergic medicine
                    <sup>
                        <xref ref-type="bibr" rid="ref-8">8</xref>
                    </sup>. Notably, the small molecules from natural database had least binding energy. Therefore, we decided to dock 1100 small molecules (see 
                    <italic toggle="yes">Extended data</italic>
                    <sup>
                        <xref ref-type="bibr" rid="ref-9">9</xref>
                    </sup>) from the ZINC Natural Products database to identify additional lead molecules against the disease.</p>
            </sec>
            <sec>
                <title>Molecular docking</title>
                <p>In this study, we utilized a bioinformatic approach that uses predictions for the arrangement of a molecule bounded to another molecule, known as molecular docking
                    <sup>
                        <xref ref-type="bibr" rid="ref-10">10</xref>,
                        <xref ref-type="bibr" rid="ref-11">11</xref>
                    </sup>. Molecular docking can be performed by two main approaches. The former describes complementation surfaces of the ligand and the protein
                    <sup>
                        <xref ref-type="bibr" rid="ref-12">12</xref>
                    </sup>. The latter simulates the docking process that calculates the free binding energy &#x0394;G while protein-ligand interaction
                    <sup>
                        <xref ref-type="bibr" rid="ref-13">13</xref>&#x2013;
                        <xref ref-type="bibr" rid="ref-15">15</xref>
                    </sup>. We have used 
                    <ext-link ext-link-type="uri" xlink:href="https://pyrx.sourceforge.io/">PyRx</ext-link> (Python prescription) version 0.8 that performs HTVS. PyRx uses Autodock, ock and Vina as docking tools. Further, MGLTools, providing a computer aided drug discovery or rational drug design pipeline to search large databases to obtain potential leads as therapeutic drugs, is present as inbuilt software in the Autodock tool of PyRx. </p>
                <p>The X-ray crystal structure of Mpro (PDB ID: 
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6M03">6M03</ext-link> (resolution: 2 &#x00c5;) was considered for our study &#x00c5;). The database considered for docking was the 
                    <ext-link ext-link-type="uri" xlink:href="http://zinc15.docking.org/substances/subsets/natural-products/">ZINC Natural Products</ext-link> database. For processing of ligands and macromolecules, the energy of 3D molecules were minimized. The Universal Force Field or UFF was used for the energy minimization of small molecules before docking. Removal of water molecules and insertion of polar hydrogen into the protein crystal structure was carried out in pre-processing of the macromolecule. Later, PDBQT files of ligands and macromolecule were generated using 
                    <ext-link ext-link-type="uri" xlink:href="http://autodock.scripps.edu/">AutoDock</ext-link> version 4. </p>
            </sec>
            <sec>
                <title>Molecular docking process</title>
                <p>The grid box was as per our previous article, with dimension coordinates of X:29.9242, Y:64.1097, and Z:48.1126 and center coordinates of X:12.2632, Y:12.3998, and Z:5.4737)
                    <sup>
                        <xref ref-type="bibr" rid="ref-8">8</xref>
                    </sup>. Maximum grid box space was chosen for docking in order to maximize the possibility of finding a good lead molecule owing to the fact that there are still no known molecule to inhibit the virus completely. Therefore, it was thought to be better to maximize the active site space. Docking was performed with the Vina software present in PyRx tool, in which the protein-ligand interaction was studied. Analysis of separate poses were done in the AutoDock and the docked pose with the least binding affinity in kcal/mol was chosen for further analysis.</p>
                <p>Conversion of these final docked ligands into PDB format was done using 
                    <ext-link ext-link-type="uri" xlink:href="https://pymol.org/2/">Pymol</ext-link> software version 1.7.4; 
                    <ext-link ext-link-type="uri" xlink:href="https://www.3ds.com/products-services/biovia/products/">Discovery studio 4.1</ext-link> was used to study their interaction. Pymol could also be used for studying the interactions. </p>
                <p>In addition, remdesivir, an antiviral agent that was found to act to some extent against this disease, was used as the reference molecule. Hence, it was initially docked with 6M03 in order to know (&#x0394;G) value as the reference range for acquiring the hits.</p>
            </sec>
        </sec>
        <sec sec-type="results">
            <title>Results</title>
            <sec>
                <title>Docking results</title>
                <p>Mpro has six stranded antiparallel beta barrels which provides the substrate binding site between domain I (10&#x2013;99 residues) and domain II (100&#x2013;182 residues)
                    <sup>
                        <xref ref-type="bibr" rid="ref-16">16</xref>
                    </sup>. Dimerization of Mpro is regulated by domain III(198&#x2013;303 residues) which is a globular cluster of five helices. It is primarily done by forming a salt-bridge interaction between Glu290 of one protomer and Arg4 of the other
                    <sup>
                        <xref ref-type="bibr" rid="ref-16">16</xref>
                    </sup>. The two molecules domain II of molecule A and the NH2-terminal residues(&#x201c;N-finger&#x201d;) of molecule B are arranged perpendicularly to one another to provide a tight dimer for Mpro
                    <sup>
                        <xref ref-type="bibr" rid="ref-16">16</xref>
                    </sup>. N-finger of each of the two protomers is found to be interacting with Glu166 of the other protomer, therefore, the N-finger is firmly pressed in between domains II and III of the parent monomer and domain II of the other monomer. Dimerization is essential for the catalytic activity of Mpro. Hence, these residues (10 to 99, 100 to 182 and 198 to 303) are essential for increasing the catalytic activity of Mpro
                    <sup>
                        <xref ref-type="bibr" rid="ref-16">16</xref>
                    </sup>. Docking results for each molecule are given in the 
                    <italic toggle="yes">Extended data</italic>
                    <sup>
                        <xref ref-type="bibr" rid="ref-9">9</xref>
                    </sup>.</p>
            </sec>
            <sec>
                <title>Docking results for top 25 molecules against SARS-CoV-2 Mpro</title>
                <p>The free binding energy for our reference molecule, which is remdesivir, was found to be -6.3 kcal/mol and it interacted with Leu272, Leu287, Tyr237, and Asn238 forming six hydrogen bonds with Lys137, Thr199, and Tyr239 residues of the main protease, Mpro (6M03). 
                    <xref ref-type="fig" rid="f1">Figure 1</xref> presents the interaction of remdesivir with Mpro.</p>
                <fig fig-type="figure" id="f1" orientation="portrait" position="float">
                    <label>Figure 1. </label>
                    <caption>
                        <title>Interaction of remdesivir with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure1.gif"/>
                </fig>
                <p>The best 25 molecules, with binding energies of -8.8 kcal/mol to -8.7 kcal/mol, were shortlisted and are depicted in 
                    <xref ref-type="table" rid="T1">Table 1</xref>. </p>
                <table-wrap id="T1" orientation="portrait" position="anchor">
                    <label>Table 1. </label>
                    <caption>
                        <title>Docking results of top 25 hits against SARS-CoV-2 Mpro.</title>
                    </caption>
                    <table content-type="article-table" frame="hsides">
                        <thead>
                            <tr>
                                <th colspan="1" rowspan="1"/>
                                <th align="left" colspan="1" rowspan="1" valign="top">Ligands
                                    <break/>Prefix
                                    <break/>
                                    <italic toggle="yes">ZINC000</italic>
                                </th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Binding
                                    <break/>affinity
                                    <break/>(kcal/mol)</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Molecule
                                    <break/>Formula</th>
                                <th align="left" colspan="1" rowspan="1" valign="top">Common name</th>
                            </tr>
                        </thead>
                        <tbody>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">1 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100061903 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>30</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>38</sub>
                                    <italic toggle="yes">N</italic>
                                    <sub>2</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>5</sub>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Ramipril Benzyl Ester </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">2 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">027865962 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>19</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>17</sub>
                                    <italic toggle="yes">NO</italic>
                                    <sub>4</sub>
                                </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Escholtzine / (S)-Stylopine </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">3 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">001205247 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>30</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>33</sub>
                                    <italic toggle="yes">NO</italic>
                                    <sub>3</sub>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4&#x2019;-(Decyloxy)-1,1&#x2019;-biphenyl-4-carboxylic acid 4-isocyanophenyl estere </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">4 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">042835388 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>35</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>56</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>7</sub>
                                </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Epocholeone </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">5 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">008783205 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>20</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>13</sub>
                                    <italic toggle="yes">N</italic>
                                    <sub>3</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>7</sub>
                                </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2,4,6-Trinitrophenol-phenanthrene(1:1) </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">6 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">004430007 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>30</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>44</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>4</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">3-Oxoglycyrrhetinic acid </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">004098157 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>20</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>24</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>6</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Lariciresinol </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">014829676 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>28</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>32</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>6</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Cochinchinone B </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">9 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">072320605 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>26</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>35</sub>
                                    <italic toggle="yes">NO</italic>
                                    <sub>6</sub>
                                </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Lactimidomycin </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">10 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">085648664 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>28</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>45</sub>
                                    <italic toggle="yes">NO</italic>
                                    <sub>3</sub>
                                </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">5-Methoxy-1-indanone O-stearoyloxime </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">11 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">085593575 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>23</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>22</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>5</sub>6 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Rotenone </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">12 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">085593490 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>32</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>32</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>11</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Methyl (E)-3-[10-(4-hydroxy-3-methoxyphenyl)-9-(hydroxymethyl)-6,13-dimethoxy-
                                    <break/>15-[(E)-3-methoxy-3-oxoprop-1-enyl]-8,11-dioxatricyclo[10.4.0.02,7] hexadeca-
                                    <break/>1(12),2(7),3,5,13,15-hexaen-4-yl]prop-2-enoate </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">13 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">085593420 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>31</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>28</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>11</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Cardinalin 4 </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">14 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">085593150 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>34</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>32</sub>
                                    <italic toggle="yes">N</italic>
                                    <sub>2</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>9</sub> </td>
                                <td align="left" colspan="1" rowspan="2" valign="top">4-[(4-Aminophenyl)methyl]aniline;4-(4-carboxy-3 -ethoxycarbonylbenzoyl)-2-
                                    <break/>ethoxycarbonylbenzoic acid [(4S,5S,6S,7S,8S,9R)-7-Anilino-8-hydroxy-8 -(hydroxymethyl)-
                                    <break/>9-(methoxymethoxy)-4,9-dimethyl-2 -phenyl-3-oxa-1-azaspiro[4.4]non-1-en-6-yl] 4-
                                    <break/>nitrobenzoate </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">15 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">085593179 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.8 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>31</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>33</sub>
                                    <italic toggle="yes">N</italic>
                                    <sub>3</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>9</sub> </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">16 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">002127691 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>26</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>34</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>6</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Cinobufagin </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">17 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">118913911 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>19</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>28</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>3</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">4-Hydroxytestosterone </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">18 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">100061900 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>30</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>38</sub>
                                    <italic toggle="yes">N</italic>
                                    <sub>2</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>5</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">6-(4-Methylpiperazin-1-yl)-6-[3-[2-(2-phenylethyl) phenoxy]propoxycarbonyl]cyclohex-3-
                                    <break/>ene-1-carboxylic acid </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">19 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">004097834 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>30</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>46</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>5</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Quillaic Acid </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">20 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">014883275 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>27</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>24</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>5</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Vitisinol C </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">21 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">015119492 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>20</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>16</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>6</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Citrusinol </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">22 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">072320614 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>31</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>43</sub>
                                    <italic toggle="yes">N</italic>
                                    <sub>7</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>6</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Segetalin A </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">23 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">085648346 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>39</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>45</sub>
                                    <italic toggle="yes">NO</italic>
                                    <sub>6</sub>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Propafenone dimer </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">24 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">085628204 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>33</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>54</sub>
                                    <italic toggle="yes">N</italic>
                                    <sub>4</sub>
                                    <italic toggle="yes">O</italic>
                                    <sub>5</sub> </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">2-[2-Methylpropanoyl(octadecyl)amino]-4-oxo-4-[(3-oxo-1,2-dihydroindazol-6-
                                    <break/>yl)amino]butanoic acid </td>
                            </tr>
                            <tr>
                                <td align="left" colspan="1" rowspan="1" valign="top">25 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">085593555 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">-8.7 </td>
                                <td align="left" colspan="1" rowspan="1" valign="top">
                                    <italic toggle="yes">C</italic>
                                    <sub>24</sub>
                                    <italic toggle="yes">H</italic>
                                    <sub>25</sub>
                                    <italic toggle="yes">NO</italic>
                                    <sub>6</sub>
</td>
                                <td align="left" colspan="1" rowspan="1" valign="top">Scopolamine 4-hydroxybenzoate </td>
                            </tr>
                        </tbody>
                    </table>
                </table-wrap>
                <p>The results obtained through the molecular docking analysis of some of the presented molecules exhibit different insights that allows asserting whether it is possible to use them for medical treatment of COVID-19.</p>
                <list list-type="bullet">
                    <list-item>
                        <p>
                            <bold>Ramipril benzyl ester</bold> forms two hydrogen bonds with Asp153 as well as Thr304 residues apart from interacting with Asn151, Phe294, Asp295, and Val303 residues of Mpro as presented in 
                            <xref ref-type="fig" rid="f2">Figure 2</xref>.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Escholtzine / (S)-stylopine</bold> forms two hydrogen bonds with Thr111 and Ile152 apart from interacting with Asp153 residues of Mpro. Its interaction is presented in 
                            <xref ref-type="fig" rid="f3">Figure 3</xref>.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>3-oxoglycyrrhetinic acid</bold> forms two hydrogen bonds with Leu287 as well as Asp289, whereas Glu288, Leu272, and Tyr239 are the other interacting residues of Mpro. 
                            <xref ref-type="fig" rid="f4">Figure 4</xref> presents 3-oxoglycyrrhetinic acid interaction with Mpro.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Lariciresinol</bold> forms a hydrogen bond with Arg298 as well as interacts with Phe294, Ile106, and Val104 residues of Mpro. 
                            <xref ref-type="fig" rid="f5">Figure 5</xref> presents the interaction of this molecule with 6M03.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Cochinchinone B</bold> forms a hydrogen bond with Arg298 along with interacting with Ile249, Pro252, Leu253, Pro293, Phe294, Val297, and Val303 residues of Mpro. The interaction of this molecule with Mpro is presented in 
                            <xref ref-type="fig" rid="f6">Figure 6</xref>
                        </p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Lactimidomycin</bold> interacts with Phe8, Phe305, Val303, Arg298, Phe294, Val297, and Val104. In addition, it forms two hydrogen bonds with Gln110 and Asp295 residues of Mpro as presented in 
                            <xref ref-type="fig" rid="f7">Figure 7</xref>.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Cardinalin 4</bold> forms five hydrogen bonds, one with Asp197 and four with Lys5 apart from interacting with other residues of Mpro such as Lys137, Met276, Leu286, Leu287, and Asp289. Its interaction with Mpro is presented in 
                            <xref ref-type="fig" rid="f8">Figure 8</xref>
                        </p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Cinobufagin</bold> forms two hydrogen bonds with Thr111 residue and interacts with Val297, Phe294, Arg298, Val303, Phe305, Phe8, and Pro252 residues of Mpro. 
                            <xref ref-type="fig" rid="f9">Figure 9</xref> presents Ccnobufagin interaction with Mpro.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Quillaic acid</bold> interacts with Val104, Phe294, Arg298, Val303, and Phe305 residues of 6M03. The quillaic acid interaction with Mpro is presented in 
                            <xref ref-type="fig" rid="f10">Figure 10</xref>.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Vitisinol C</bold> forms two hydrogen bonds with Asn151 and Arg298 apart from interacting with Gln110, Phe294, Val297, Val303, and Phe8. 
                            <xref ref-type="fig" rid="f11">Figure 11</xref> presents vitisinol C interaction with Mpro.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Citrusinol</bold> forms four hydrogen bonds with two residues, Asn151 and Gln110, as well as interacts with Val297, Arg298, and Val303 residues of Mpro. 
                            <xref ref-type="fig" rid="f12">Figure 12</xref> presents its interaction with Mpro.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Segetalin A</bold> forms three hydrogen bonds with Gln110, Ser158, and Asp153 and interacting with residues such as Phe294, Arg298, Val303 of Mpro. 
                            <xref ref-type="fig" rid="f13">Figure 13</xref> presents segetalin A interaction with 6M03.</p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Propafenone dimer</bold> interacts with Gln110, Phe294, Arg298, Val303, and Phe305 and forms two hydrogen bonds with Thr111 and Asn151 of Mpro residues as presented in 
                            <xref ref-type="fig" rid="f14">Figure 14</xref>
                        </p>
                    </list-item>
                    <list-item>
                        <p>
                            <bold>Scopolamine 4-hydroxybenzoate</bold> forms hydrogen bonds with Phe294 and Thr304 apart from interacting with Asp295 and Val303 residues of Mpro. 
                            <xref ref-type="fig" rid="f15">Figure 15</xref> presents the scopolamine 4-hydroxybenzoate interaction.</p>
                    </list-item>
                </list>
                <fig fig-type="figure" id="f2" orientation="portrait" position="float">
                    <label>Figure 2. </label>
                    <caption>
                        <title>Interaction of ramipril benzyl ester with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure2.gif"/>
                </fig>
                <fig fig-type="figure" id="f3" orientation="portrait" position="float">
                    <label>Figure 3. </label>
                    <caption>
                        <title>Interaction of escholtzine / (S)-stylopine with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure3.gif"/>
                </fig>
                <fig fig-type="figure" id="f4" orientation="portrait" position="float">
                    <label>Figure 4. </label>
                    <caption>
                        <title>Interaction of 3-oxoglycyrrhetinic acid with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure4.gif"/>
                </fig>
                <fig fig-type="figure" id="f5" orientation="portrait" position="float">
                    <label>Figure 5. </label>
                    <caption>
                        <title>Interaction of lariciresinol with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure5.gif"/>
                </fig>
                <fig fig-type="figure" id="f6" orientation="portrait" position="float">
                    <label>Figure 6. </label>
                    <caption>
                        <title>Interaction of cochinchinone B with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure6.gif"/>
                </fig>
                <fig fig-type="figure" id="f7" orientation="portrait" position="float">
                    <label>Figure 7. </label>
                    <caption>
                        <title>Interaction of lactimidomycin with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure7.gif"/>
                </fig>
                <fig fig-type="figure" id="f8" orientation="portrait" position="float">
                    <label>Figure 8. </label>
                    <caption>
                        <title>Interaction of cardinalin 4 with 6M03.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure8.gif"/>
                </fig>
                <fig fig-type="figure" id="f9" orientation="portrait" position="float">
                    <label>Figure 9. </label>
                    <caption>
                        <title>Interaction of cinobufagin with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure9.gif"/>
                </fig>
                <fig fig-type="figure" id="f10" orientation="portrait" position="float">
                    <label>Figure 10. </label>
                    <caption>
                        <title>Interaction of quillaic acid with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure10.gif"/>
                </fig>
                <fig fig-type="figure" id="f11" orientation="portrait" position="float">
                    <label>Figure 11. </label>
                    <caption>
                        <title>Interaction of vitisinol C with 6M03.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure11.gif"/>
                </fig>
                <fig fig-type="figure" id="f12" orientation="portrait" position="float">
                    <label>Figure 12. </label>
                    <caption>
                        <title>Interaction of citrusinol with 6M03.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure12.gif"/>
                </fig>
                <fig fig-type="figure" id="f13" orientation="portrait" position="float">
                    <label>Figure 13. </label>
                    <caption>
                        <title>Interaction of segetalin A with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure13.gif"/>
                </fig>
                <fig fig-type="figure" id="f14" orientation="portrait" position="float">
                    <label>Figure 14. </label>
                    <caption>
                        <title>Interaction of propafenone dimer with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure14.gif"/>
                </fig>
                <fig fig-type="figure" id="f15" orientation="portrait" position="float">
                    <label>Figure 15. </label>
                    <caption>
                        <title>Interaction of scopolamine 4-hydroxybenzoate with Mpro.</title>
                    </caption>
                    <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure15.gif"/>
                </fig>
            </sec>
        </sec>
        <sec sec-type="discussion">
            <title>Discussion</title>
            <p>Natural molecules are known derivatives of most of the present drugs in use against many diseases. In this study, we have also found some good leads and most of the 25 selected molecules show medicinal properties. Ramipril benzyl ester (protected form of ramipril), which is an inhibitor of angiotensin-converting enzyme ACE is the host receptor protein where the SARS-CoV-2 spike protein binds. Ramiprilat, which is an active compound of ramipril benzyl ester, is formed on the hydrolysis of the ester group, which later inhibits ACE. This leads to the prevention of the catalytic conversion of angiotensin I to angiotensin II that causes vasodilation
                <sup>
                    <xref ref-type="bibr" rid="ref-17">17</xref>
                </sup>. Stylopine
                <sup>
                    <xref ref-type="bibr" rid="ref-18">18</xref>
                </sup> and quillaic acid exhibits anti-inflammatory activity
                <sup>
                    <xref ref-type="bibr" rid="ref-19">19</xref>
                </sup>. Cinobufagin, CBF, has antitumor activity as it is known to inhibit the growth of PC3 cells both 
                <italic toggle="yes">in vitro</italic> and 
                <italic toggle="yes">in vivo</italic> along with inducing apoptosis of tumor cells as per reports
                <sup>
                    <xref ref-type="bibr" rid="ref-20">20</xref>
                </sup>. It was found that intake of the plant ligands such as lariciresinol reduced endothelial dysfunction and vascular inflammation in post-menopausal women and middle aged/elderly men
                <sup>
                    <xref ref-type="bibr" rid="ref-21">21</xref>
                </sup>. Vitisinol C as per earlier reports was found to exhibit an essential activity against amyloid aggregation, which is present in 
                <italic toggle="yes">Vitis vinifera</italic> grapevine shoots
                <sup>
                    <xref ref-type="bibr" rid="ref-22">22</xref>
                </sup>.</p>
            <p>Segetalins are known to have vasorelaxant activity
                <sup>
                    <xref ref-type="bibr" rid="ref-23">23</xref>
                </sup>. Scopolamine is known as antimuscarinics that blocks the effects of certain natural substance (acetylcholine) on the central nervous system, it is also used to prevent nausea and vomiting caused by motion sickness or medications used during surgery
                <sup>
                    <xref ref-type="bibr" rid="ref-24">24</xref>
                </sup>.</p>
            <p>3-oxo-glycyrrhetinic acid has antitumor activity and expectorant (antitussive) properties
                <sup>
                    <xref ref-type="bibr" rid="ref-25">25</xref>
                </sup>. Lactimidomycin has antifungal, antiviral, and anti-cancer properties apart from acting as a direct inhibitor of protein translation inribosomes which is a glutarimide antibiotic derived from the bacterium 
                <italic toggle="yes">Streptomyces amphibiosporus</italic>
                <sup>
                    <xref ref-type="bibr" rid="ref-26">26</xref>
                </sup>. Cardinalins dinalins 4 exhibit anti-cancer properties. Conchinone B has an antioxidant activity. Rotenone used to treat head lice on humans, scabies, and parasitic mites on chickens, livestock, and pet animals. Propafenone is used for the treatment of irregular heartbeat like atrial fibrillation, paroxysmal supraventricular and tachycardia in order to restore normal heart rhythm for maintaining a regular, steady heartbeat
                <sup>
                    <xref ref-type="bibr" rid="ref-27">27</xref>
                </sup>. These small molecules or potential drugs could be used as therapeutics for COVID-19 disease due to their binding affinity with the viral protein as well as interaction with Mpro. These small molecules were found to interact with the residues involved in enhancing the catalytic activity of Mpro or SARS CoV-2 main protease. Therefore, these could prove to play important role in inhibiting the viral activity. However, there are three small molecules ramipril benzyl ester, propafenone dimer and lariciresinol found from this study that might prove to be useful against this virus especially due to their present medical application, docking score and interaction with Mpro, as illustrated in 
                <xref ref-type="fig" rid="f16">Figure 16</xref>, 
                <xref ref-type="fig" rid="f17">Figure 17</xref> and 
                <xref ref-type="fig" rid="f18">Figure 18</xref>.</p>
            <fig fig-type="figure" id="f16" orientation="portrait" position="float">
                <label>Figure 16. </label>
                <caption>
                    <title>Propafenone dimer interaction image with whole Mpro, main protease(6M03) of SARS-CoV-2.</title>
                </caption>
                <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure16.gif"/>
            </fig>
            <fig fig-type="figure" id="f17" orientation="portrait" position="float">
                <label>Figure 17. </label>
                <caption>
                    <title>Lariciresinol interaction image with whole Mpro, main protease(6M03) of SARS-CoV-2.</title>
                </caption>
                <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure17.gif"/>
            </fig>
            <fig fig-type="figure" id="f18" orientation="portrait" position="float">
                <label>Figure 18. </label>
                <caption>
                    <title>Ramipril Benzyl Ester interaction image with whole Mpro, main protease(6M03) of SARS-CoV-2.</title>
                </caption>
                <graphic orientation="portrait" position="float" xlink:href="https://f1000research-files.f1000.com/manuscripts/29515/45da90a3-fd7b-4793-a96a-3c37705244bb_figure18.gif"/>
            </fig>
        </sec>
        <sec sec-type="conclusions">
            <title>Conclusions</title>
            <p>Ramipril benzyl ester, stylopine, quillaic acid, cinobufagin, vitisinol C, segetalin A, scopolamine, 3-oxo glycyrrhetinic acid, lariciresinol, conchinone B, lactimidomycin, cardinalins 4, and propafenone dimer are 13 molecules that are predicted to form good interaction with Mpro. These molecules showed better binding affinity for Mpro than the reference molecule. Ramipril benzyl ester, apart from binding to the main protease of the virus, was also found to inhibit the virus receptor ACE present in humans. ACE2 is the receptor to which virus spike protein is known to bind to the host. The spike protein and Mpro of the SARS-CoV-2 virus are responsible for the virulence of the virus. Ramipril benzyl ester drug is reported to inhibit ACE and also found to inhibit main protease of SARS-CoV-2 virus from this study. Ramipril benzyl ester is presently used against heart stroke. Ramipril benzyl ester and propafenone are two important small molecules found from our study due to their present medicinal use as drugs for other diseases in human along with lariciresinol due to its medical application as stated in the discussion. As a result, these molecules have medicinal properties which could be used for the treatment of COVID-19 disease after further evaluation. This study presents a significant possibility in finding the cure for the COVID-19 disease from the drugs repurposing point of view. The drug targets mentioned in our study could bring relief to all those who are infected with the disease and these may also act as a prophylactic treatment when tested by the frontline healthcare providers. This study could provide relief to everyone if the drugs mentioned in our study proved to inhibit the virus in COVID19 positive patients since they are known natural derivatives with minimal side effects in individuals. Thus, our study could help in flattening the curve with speedy recovery in COVID -19 positive patients.</p>
        </sec>
        <sec>
            <title>Data availability</title>
            <sec>
                <title>Source data</title>
                <p>The COVID-19 main protease structure was downloaded from the Protein Data Bank, ID 6M03: 
                    <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org/structure/6M03">https://www.rcsb.org/structure/6M03</ext-link>. </p>
                <p>Ligands were obtained from the Zinc Natural Products database (
                    <ext-link ext-link-type="uri" xlink:href="http://zinc.docking.org/"/>). </p>
            </sec>
            <sec>
                <title>Extended data</title>
                <p>Zenodo: Molecular Docking ZINC DB. 
                    <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.4050576">https://doi.org/10.5281/zenodo.4050576</ext-link>
                    <sup>
                        <xref ref-type="bibr" rid="ref-9">9</xref>
                    </sup>. </p>
                <p>This project contains the following extended data:</p>
                <list list-type="bullet">
                    <list-item>
                        <p>Docking results for thee 100 best molecules (XLSX).</p>
                    </list-item>
                    <list-item>
                        <p>Interaction_images_viral_protein_molecules (subfolder). (Interaction images of the best 42 molecules.)</p>
                    </list-item>
                    <list-item>
                        <p>Zinc_natural_database_pdbqt_minimized (subfolder). (Molecular docking results for 1100 small molecules from the ZINC Natural Products database.)</p>
                    </list-item>
                </list>
                <p>Extended data are available under the terms of the 
                    <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/legalcode">Creative Commons Attribution 4.0 International license</ext-link> (CCBY 4.0).</p>
            </sec>
        </sec>
    </body>
    <back>
        <ack>
            <title>Acknowledgements</title>
            <p>The authors would like to acknowledge the ITI research group members for their valuable feedback.</p>
        </ack>
        <ref-list>
            <ref id="ref-1">
                <label>1</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chowdhury</surname>
                            <given-names>MS</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rathod</surname>
                            <given-names>J</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Gernsheimer</surname>
                            <given-names>J</given-names>
                        </name>
</person-group>:
                    <article-title>A Rapid Systematic Review of Clinical Trials Utilizing Chloroquine and Hydroxychloroquine as a Treatment for COVID-19.</article-title>
                    <source>

                        <italic toggle="yes">Acad Emerg Med.</italic>
</source>
                    <year>2020</year>;<volume>27</volume>(<issue>6</issue>):<fpage>493</fpage>&#x2013;<lpage>504</lpage>.
                    <pub-id pub-id-type="pmid">32359203</pub-id>
                    <pub-id pub-id-type="doi">10.1111/acem.14005</pub-id>
                    <pub-id pub-id-type="pmcid">7267507</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-2">
                <label>2</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Vermund</surname>
                            <given-names>SH</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pitzer</surname>
                            <given-names>VE</given-names>
                        </name>
</person-group>:
                    <article-title>Asymptomatic transmission and the infection fatality risk for COVID-19: Implications for school reopening.</article-title>
                    <source>

                        <italic toggle="yes">Clin Infect Dis.</italic>
</source>
                    <year>2020</year>;<fpage>ciaa855</fpage>.
                    <pub-id pub-id-type="pmid">32584967</pub-id>
                    <pub-id pub-id-type="doi">10.1093/cid/ciaa855</pub-id>
                    <pub-id pub-id-type="pmcid">7337644</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-3">
                <label>3</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Florez</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Singh</surname>
                            <given-names>S</given-names>
                        </name>
</person-group>:
                    <article-title>Online dashboard and data analysis approach for assessing COVID-19 case and death data [version 1; peer review: 2 approved, 1 approved with reservations.</article-title>
                    <source>

                        <italic toggle="yes">F1000Res.</italic>
</source>
                    <year>2020</year>;<volume>9</volume>(<issue>570</issue>):<fpage>570</fpage>.
                    <pub-id pub-id-type="pmid">32884676</pub-id>
                    <pub-id pub-id-type="doi">10.12688/f1000research.24164.1</pub-id>
                    <pub-id pub-id-type="pmcid">7450472</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-4">
                <label>4</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Jin</surname>
                            <given-names>Z</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Du</surname>
                            <given-names>X</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Xu</surname>
                            <given-names>Y</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Structure of M
                        <sup>pro</sup> from SARS-CoV-2 and discovery of its inhibitors.</article-title>
                    <source>

                        <italic toggle="yes">Nature.</italic>
</source>
                    <year>2020</year>;<volume>582</volume>(<issue>7811</issue>):<fpage>289</fpage>&#x2013;<lpage>293</lpage>.
                    <pub-id pub-id-type="pmid">32272481</pub-id>
                    <pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-5">
                <label>5</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Perinel</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Launay</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Botelho-Nevers</surname>
                            <given-names>&#x00c9;</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients.</article-title>
                    <source>

                        <italic toggle="yes">Clin Infect Dis.</italic>
</source>
                    <year>2020</year>;<fpage>ciaa394</fpage>.
                    <pub-id pub-id-type="pmid">32255489</pub-id>
                    <pub-id pub-id-type="doi">10.1093/cid/ciaa394</pub-id>
                    <pub-id pub-id-type="pmcid">7184449</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-6">
                <label>6</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Ferner</surname>
                            <given-names>RE</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Aronson</surname>
                            <given-names>JK</given-names>
                        </name>
</person-group>:
                    <article-title>Chloroquine and hydroxychloroquine in covid-19.</article-title>
                    <source>

                        <italic toggle="yes">BMJ.</italic>
</source>
                    <year>2020</year>;<volume>369</volume>:<fpage>m14324</fpage>.
                    <pub-id pub-id-type="pmid">32269046</pub-id>
                    <pub-id pub-id-type="doi">10.1136/bmj.m1432</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-7">
                <label>7</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hall</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ji</surname>
                            <given-names>HF</given-names>
                        </name>
</person-group>:
                    <article-title>A search for medications to treat COVID-19 via 
                        <italic toggle="yes">in silico</italic> molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease.</article-title>
                    <source>

                        <italic toggle="yes">Travel Med Infect Dis.</italic>
</source>
                    <year>2020</year>;<volume>35</volume>:<fpage>101646</fpage>.
                    <pub-id pub-id-type="pmid">32294562</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.tmaid.2020.101646</pub-id>
                    <pub-id pub-id-type="pmcid">7152904</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-8">
                <label>8</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Singh</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Florez</surname>
                            <given-names>H</given-names>
                        </name>
</person-group>:
                    <article-title>Coronavirus disease 2019 drug discovery through molecular docking [version 1; peer review: 1 approved, 2 approved with reservations].</article-title>
                    <source>

                        <italic toggle="yes">F1000Res.</italic>
</source>
                    <year>2020</year>;<volume>9</volume>:<fpage>502</fpage>.
                    <pub-id pub-id-type="pmid">32704354</pub-id>
                    <pub-id pub-id-type="doi">10.12688/f1000research.24218.1</pub-id>
                    <pub-id pub-id-type="pmcid">7361499</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-9">
                <label>9</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Singh</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Florez</surname>
                            <given-names>H</given-names>
                        </name>
</person-group>:
                    <article-title>Molecular docking COVID-19</article-title>.<year>2020</year>.
                    <ext-link ext-link-type="uri" xlink:href="http://www.doi.org/10.5281/zenodo.3840625">http://www.doi.org/10.5281/zenodo.3840625</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref-10">
                <label>10</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Salvatierra</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Florez</surname>
                            <given-names>H</given-names>
                        </name>
</person-group>:
                    <article-title>Bioinformatics Approach to Analyze Influenza Viruses</article-title>.
In:
                    <italic toggle="yes">Workshop on Engineering Applications.</italic>
                    <year>2018</year>;<volume>916</volume>:<fpage>442</fpage>&#x2013;<lpage>452</lpage>.
                    <pub-id pub-id-type="doi">10.1007/978-3-030-00353-1_39</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-11">
                <label>11</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Lengauer</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Rarey</surname>
                            <given-names>M</given-names>
                        </name>
</person-group>:
                    <article-title>Computational methods for biomolecular docking.</article-title>
                    <source>

                        <italic toggle="yes">Curr Opin Struct Biol.</italic>
</source>
                    <year>1996</year>;<volume>6</volume>(<issue>3</issue>):<fpage>402</fpage>&#x2013;<lpage>406</lpage>.
                    <pub-id pub-id-type="pmid">8804827</pub-id>
                    <pub-id pub-id-type="doi">10.1016/s0959-440x(96)80061-3</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-12">
                <label>12</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Goldman</surname>
                            <given-names>BB</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Wipke</surname>
                            <given-names>WT</given-names>
                        </name>
</person-group>:
                    <article-title>QSD quadratic shape descriptors. 2. Molecular docking using quadratic shape descriptors (QSDock).</article-title>
                    <source>

                        <italic toggle="yes">Proteins.</italic>
</source>
                    <year>2000</year>;<volume>38</volume>(<issue>1</issue>):<fpage>79</fpage>&#x2013;<lpage>94</lpage>.
                    <pub-id pub-id-type="pmid">10651041</pub-id>
                    <pub-id pub-id-type="doi">10.1002/(SICI)1097-0134(20000101)38:1&lt;79::AID-PROT9&gt;3.0.CO;2-U</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-13">
                <label>13</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Hector</surname>
                            <given-names>F</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Karina</surname>
                            <given-names>S</given-names>
                        </name>
</person-group>:
                    <article-title>Bioinformatics study of mutations of resistance to antivirals in the ns5a gen of hcv.</article-title>
                    <source>

                        <italic toggle="yes">International Information Institute (Tokyo). Information.</italic>
</source>
                    <year>2017</year>;<volume>20</volume>(<issue>9A</issue>):<fpage>6665</fpage>&#x2013;<lpage>6672</lpage>.
                    <ext-link ext-link-type="uri" xlink:href="https://www.researchgate.net/publication/322771606_Bioinformatics_study_of_mutations_of_resistance_to_antivirals_in_the_NS5A_Gen_of_HCV">Reference Source</ext-link>
                </mixed-citation>
            </ref>
            <ref id="ref-14">
                <label>14</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Feig</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Onufriev</surname>
                            <given-names>A</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>MS</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Performance comparison of generalized born and Poisson methods in the calculation of electrostatic solvation energies for protein structures.</article-title>
                    <source>

                        <italic toggle="yes">J Comput Chem.</italic>
</source>
                    <year>2004</year>;<volume>25</volume>(<issue>2</issue>):<fpage>265</fpage>&#x2013;<lpage>284</lpage>.
                    <pub-id pub-id-type="pmid">14648625</pub-id>
                    <pub-id pub-id-type="doi">10.1002/jcc.10378</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-15">
                <label>15</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Salvatierra</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Vera</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Florez</surname>
                            <given-names>H</given-names>
                        </name>
</person-group>:
                    <article-title>Bioinformatics methods to discover antivirals against zika virus</article-title>. In
                    <italic toggle="yes">International Conference on Applied Informatics</italic>.<year>2019</year>;<volume>1051</volume>:<fpage>3</fpage>&#x2013;<lpage>14</lpage>.
                    <pub-id pub-id-type="doi">10.1007/978-3-030-32475-9_1</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-16">
                <label>16</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Zhang</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lin</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sun</surname>
                            <given-names>X</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved &#x03b1;-ketoamide inhibitors.</article-title>
                    <source>

                        <italic toggle="yes">Science.</italic>
</source>
                    <year>2020</year>;<volume>368</volume>(<issue>6489</issue>):<fpage>409</fpage>&#x2013;<lpage>412</lpage>.
                    <pub-id pub-id-type="pmid">32198291</pub-id>
                    <pub-id pub-id-type="doi">10.1126/science.abb3405</pub-id>
                    <pub-id pub-id-type="pmcid">7164518</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-17">
                <label>17</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <collab>Heart Outcomes Prevention Evaluation Study Investigators, </collab>

                        <name name-style="western">
                            <surname>Yusuf</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sleight</surname>
                            <given-names>P</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.</article-title>
                    <source>

                        <italic toggle="yes">N Engl J Med.</italic>
</source>
                    <year>2000</year>;<volume>342</volume>(<issue>3</issue>):<fpage>145</fpage>&#x2013;<lpage>53</lpage>.
                    <pub-id pub-id-type="pmid">10639539</pub-id>
                    <pub-id pub-id-type="doi">10.1056/NEJM200001203420301</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-18">
                <label>18</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Jang</surname>
                            <given-names>SI</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Kim</surname>
                            <given-names>B</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lee</surname>
                            <given-names>WY</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Stylopine from 
                        <italic toggle="yes">Chelidonium majus</italic> inhibits LPS-induced inflammatory mediators in RAW 264.7 cells.</article-title>
                    <source>

                        <italic toggle="yes">Arch Pharm Res.</italic>
</source>
                    <year>2004</year>;<volume>27</volume>(<issue>9</issue>):<fpage>923</fpage>&#x2013;<lpage>9</lpage>.
                    <pub-id pub-id-type="pmid">15473662</pub-id>
                    <pub-id pub-id-type="doi">10.1007/BF02975845</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-19">
                <label>19</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Rodr&#x00ed;guez-D&#x00ed;az</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Delporte</surname>
                            <given-names>C</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Cartagena</surname>
                            <given-names>C</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Topical anti-inflammatory activity of quillaic acid from 
                        <italic toggle="yes">Quillaja saponaria</italic> Mol. and some derivatives.</article-title>
                    <source>

                        <italic toggle="yes"> J Pharm Pharmacol.</italic>
</source>
                    <year>2011</year>;<volume>63</volume>(<issue>5</issue>):<fpage>718</fpage>&#x2013;<lpage>724</lpage>.
                    <pub-id pub-id-type="pmid">21492174</pub-id>
                    <pub-id pub-id-type="doi">10.1111/j.2042-7158.2011.01263.x</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-20">
                <label>20</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Niu</surname>
                            <given-names>T</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Zhao</surname>
                            <given-names>L</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lin</surname>
                            <given-names>X</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Cinobufagin, a bufadienolide from traditional Chinese medicine 
                        <italic toggle="yes">Bufo bufo gargarizans</italic> CANTOR, inhibits PC3 cell growth 
                        <italic toggle="yes">in vitro</italic> and 
                        <italic toggle="yes">in vivo</italic>.</article-title>
                    <source>

                        <italic toggle="yes">Journal of Traditional Chinese Medical Sciences.</italic>
</source>
                    <year>2019</year>;<volume>6</volume>(<issue>2</issue>):<fpage>175</fpage>&#x2013;<lpage>183</lpage>.
                    <pub-id pub-id-type="doi">10.1016/j.jtcms.2019.03.005</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-21">
                <label>21</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Pellegrini</surname>
                            <given-names>N</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Valtue&#x00f1;a</surname>
                            <given-names>S</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Ardig&#x00f2;</surname>
                            <given-names>D</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Intake of the plant lignans matairesinol, secoisolariciresinol, pinoresinol, and lariciresinol in relation to vascular inflammation and endothelial dysfunction in middle age-elderly men and post-menopausal women living in Northern Italy.</article-title>
                    <source>

                        <italic toggle="yes">Nutr Metab Cardiovasc Dis.</italic>
</source>
                    <year>2010</year>;<volume>20</volume>(<issue>1</issue>):<fpage>64</fpage>&#x2013;<lpage>71</lpage>.
                    <pub-id pub-id-type="pmid">19361969</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.numecd.2009.02.003</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-22">
                <label>22</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Chaher</surname>
                            <given-names>N</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Arraki</surname>
                            <given-names>K</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Dillinseger</surname>
                            <given-names>E</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Bioactive stilbenes from 
                        <italic toggle="yes">Vitis vinifera</italic> grapevine shoots extracts.</article-title>
                    <source>

                        <italic toggle="yes">J Sci Food Agric.</italic>
</source>
                    <year>2014</year>;<volume>94</volume>(<issue>5</issue>):<fpage>951</fpage>&#x2013;<lpage>954</lpage>.
                    <pub-id pub-id-type="pmid">23929536</pub-id>
                    <pub-id pub-id-type="doi">10.1002/jsfa.6341</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-23">
                <label>23</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Morita</surname>
                            <given-names>H</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Eda</surname>
                            <given-names>M</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Iizuka</surname>
                            <given-names>T</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Structure of a new cyclic nonapeptide, segetalin F, and vasorelaxant activity of segetalins from 
                        <italic toggle="yes">Vaccaria segetalis</italic>.</article-title>
                    <source>

                        <italic toggle="yes">Bioorg Med Chem Lett.</italic>
</source>
                    <year>2006</year>;<volume>16</volume>(<issue>17</issue>):<fpage>4458</fpage>&#x2013;<lpage>4461</lpage>.
                    <pub-id pub-id-type="pmid">16844371</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.bmcl.2006.06.083</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-24">
                <label>24</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Thomas</surname>
                            <given-names>E</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Snyder</surname>
                            <given-names>PJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Pietrzak</surname>
                            <given-names>RH</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults.</article-title>
                    <source>

                        <italic toggle="yes">Neuropsychologia.</italic>
</source>
                    <year>2008</year>;<volume>46</volume>(<issue>10</issue>):<fpage>2476</fpage>&#x2013;<lpage>2484</lpage>.
                    <pub-id pub-id-type="pmid">18514746</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.neuropsychologia.2008.04.010</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-25">
                <label>25</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Maitraie</surname>
                            <given-names>D</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Hung</surname>
                            <given-names>CF</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Tu</surname>
                            <given-names>HY</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Synthesis, anti-inflammatory, and antioxidant activities of 18beta-glycyrrhetinic acid derivatives as chemical mediators and xanthine oxidase inhibitors.</article-title>
                    <source>

                        <italic toggle="yes">Bioorg Med Chem.</italic>
</source>
                    <year>2009</year>;<volume>17</volume>(<issue>7</issue>):<fpage>2785</fpage>&#x2013;<lpage>2792</lpage>.
                    <pub-id pub-id-type="pmid">19278854</pub-id>
                    <pub-id pub-id-type="doi">10.1016/j.bmc.2009.02.025</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-26">
                <label>26</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Larsen</surname>
                            <given-names>BJ</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Sun</surname>
                            <given-names>Z</given-names>
                        </name>

                        <name name-style="western">
                            <surname>Lachacz</surname>
                            <given-names>E</given-names>
                        </name>

                        <etal/>
</person-group>:
                    <article-title>Synthesis and Biological Evaluation of Lactimidomycin and Its Analogues.</article-title>
                    <source>

                        <italic toggle="yes">Chemistry.</italic>
</source>
                    <year>2015</year>;<volume>21</volume>(<issue>52</issue>):<fpage>19159</fpage>&#x2013;<lpage>19167</lpage>.
                    <pub-id pub-id-type="pmid">26577990</pub-id>
                    <pub-id pub-id-type="doi">10.1002/chem.201503527</pub-id>
                </mixed-citation>
            </ref>
            <ref id="ref-27">
                <label>27</label>
                <mixed-citation publication-type="journal">
                    <person-group person-group-type="author">

                        <name name-style="western">
                            <surname>Komatsu</surname>
                            <given-names>T</given-names>
                        </name>
</person-group>:
                    <article-title>Current strategies of antiarrhythmic drug therapy for paroxysmal atrial &#xfb01;brillation.</article-title>
                    <source>

                        <italic toggle="yes">J Arrhythm.</italic>
</source>
                    <year>2012</year>;<volume>28</volume>(<issue>3</issue>):<fpage>162</fpage>&#x2013;<lpage>169</lpage>.
                    <pub-id pub-id-type="doi">10.1016/j.joa.2012.05.003</pub-id>
                </mixed-citation>
            </ref>
        </ref-list>
    </back>
    <sub-article article-type="reviewer-report" id="report72544">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.29515.r72544</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Pollo-Cattaneo</surname>
                        <given-names>Maria Florencia</given-names>
                    </name>
                    <xref ref-type="aff" rid="r72544a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-4197-3880</uri>
                </contrib>
                <aff id="r72544a1">
                    <label>1</label>Information System Methodologies Research Group GEMIS, National Technological University of Buenos Aires, Buenos Aires, Argentina</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>23</day>
                <month>10</month>
                <year>2020</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2020 Pollo-Cattaneo MF</copyright-statement>
                <copyright-year>2020</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport72544" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.26731.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>The article proposes a study for the search of drugs to combat COVID-19. This search will be carried out by virtually screened the Zinc natural database using&#x00a0;HTVS tool through molecular docking studies to analyze molecules recommended for the treatment of COVID-19.</p>
            <p> </p>
            <p> The methodology used is consistent with the objective and the results are promising.</p>
            <p> </p>
            <p> Researchers are encouraged to continue with the proposed line and advance their research.</p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Yes</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>Yes</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>Yes</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Yes</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Artificial IntelligenceIntelligent Systems</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p>
        </body>
    </sub-article>
    <sub-article article-type="reviewer-report" id="report72545">
        <front-stub>
            <article-id pub-id-type="doi">10.5256/f1000research.29515.r72545</article-id>
            <title-group>
                <article-title>Reviewer response for version 1</article-title>
            </title-group>
            <contrib-group>
                <contrib contrib-type="author">
                    <name>
                        <surname>Ghosh</surname>
                        <given-names>Pritha</given-names>
                    </name>
                    <xref ref-type="aff" rid="r72545a1">1</xref>
                    <role>Referee</role>
                    <uri content-type="orcid">https://orcid.org/0000-0003-3641-6393</uri>
                </contrib>
                <aff id="r72545a1">
                    <label>1</label>nference Labs, Bangalore, India</aff>
            </contrib-group>
            <author-notes>
                <fn fn-type="conflict">
                    <p>
                        <bold>Competing interests: </bold>No competing interests were disclosed.</p>
                </fn>
            </author-notes>
            <pub-date pub-type="epub">
                <day>12</day>
                <month>10</month>
                <year>2020</year>
            </pub-date>
            <permissions>
                <copyright-statement>Copyright: &#x00a9; 2020 Ghosh P</copyright-statement>
                <copyright-year>2020</copyright-year>
                <license xlink:href="https://creativecommons.org/licenses/by/4.0/">
                    <license-p>This is an open access peer review report distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
                </license>
            </permissions>
            <related-article ext-link-type="doi" id="relatedArticleReport72545" related-article-type="peer-reviewed-article" xlink:href="10.12688/f1000research.26731.1"/>
            <custom-meta-group>
                <custom-meta>
                    <meta-name>recommendation</meta-name>
                    <meta-value>approve</meta-value>
                </custom-meta>
            </custom-meta-group>
        </front-stub>
        <body>
            <p>The manuscript by Singh and Florez presents the discovery of drugs against COVID19 using molecular docking methods.</p>
            <p> </p>
            <p> 
                <bold>Major:</bold> 
                <list list-type="order">
                    <list-item>
                        <p>It might be worthwhile to re-check the binding affinity values for the top hits because all of the top 15 hits have a value of -8.8 kcal/mol. Does this mean that these drugs are equally effective and can be used interchangeably?</p>
                    </list-item>
                    <list-item>
                        <p>The authors have also not discussed the importance of the residues Tyr237, Leu272, Leu287 etc. Are these known to be critical residues in the functioning of the main protease?</p>
                    </list-item>
                </list> 
                <bold>Minor:</bold> 
                <list list-type="order">
                    <list-item>
                        <p>Please use a uniform nomenclature (COVID 19 or COVID-19).</p>
                    </list-item>
                    <list-item>
                        <p>The manuscript needs to be proofread by a proficient English speaker.</p>
                    </list-item>
                </list>
            </p>
            <p>Is the work clearly and accurately presented and does it cite the current literature?</p>
            <p>Yes</p>
            <p>If applicable, is the statistical analysis and its interpretation appropriate?</p>
            <p>Not applicable</p>
            <p>Are all the source data underlying the results available to ensure full reproducibility?</p>
            <p>Yes</p>
            <p>Is the study design appropriate and is the work technically sound?</p>
            <p>Yes</p>
            <p>Are the conclusions drawn adequately supported by the results?</p>
            <p>Yes</p>
            <p>Are sufficient details of methods and analysis provided to allow replication by others?</p>
            <p>Yes</p>
            <p>Reviewer Expertise:</p>
            <p>Bioinformatics</p>
            <p>I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.</p>
        </body>
    </sub-article>
</article>
